Ralf Clemens

9.3k total citations · 1 hit paper
140 papers, 4.9k citations indexed

About

Ralf Clemens is a scholar working on Epidemiology, Infectious Diseases and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Ralf Clemens has authored 140 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Epidemiology, 60 papers in Infectious Diseases and 27 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Ralf Clemens's work include Viral gastroenteritis research and epidemiology (32 papers), SARS-CoV-2 and COVID-19 Research (26 papers) and Vaccine Coverage and Hesitancy (23 papers). Ralf Clemens is often cited by papers focused on Viral gastroenteritis research and epidemiology (32 papers), SARS-CoV-2 and COVID-19 Research (26 papers) and Vaccine Coverage and Hesitancy (23 papers). Ralf Clemens collaborates with scholars based in Germany, United States and United Kingdom. Ralf Clemens's co-authors include Nicholas J. White, Sasithon Pukrittayakamee, Markus Knuf, Theodore F. Tsai, Timo Vesikari, Sornchai Looareesuwan, Sue Ann Costa Clemens, Astrid Borkowski, S Vanijanonta and Giovanni Della Cioppa and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Hepatology.

In The Last Decade

Ralf Clemens

139 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

2017 373 citations Ralf Clemens et al. The Lancet profile →

Peers

Countries citing papers authored by Ralf Clemens

Since Specialization

Citations

This map shows the geographic impact of Ralf Clemens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralf Clemens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralf Clemens more than expected).

Fields of papers citing papers by Ralf Clemens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralf Clemens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralf Clemens. The network helps show where Ralf Clemens may publish in the future.

Co-authorship network of co-authors of Ralf Clemens

This figure shows the co-authorship network connecting the top 25 collaborators of Ralf Clemens. A scholar is included among the top collaborators of Ralf Clemens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralf Clemens. Ralf Clemens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Boosting with adjuvanted SCB-2019 elicits superior Fcγ-receptor engagement driven by IgG3 to SARS-CoV-2 spike 2024 ·npj Vaccines ·Wonyeong Jung, Dansu Yuan, Benjamin P. Kellman, (unknown), Ralf Clemens, Eveline Pı́polo Milan, Eduardo Sprinz, José Cerbino-Neto, Igor Smolenov, Galit Alter, Ryan P. McNamara, Sue Ann Costa Clemens	2
2	Novel Oral Polio Vaccine Type 2 Use for Polio Outbreak Response: A Global Effort for a Global Health Emergency 2024 ·Pathogens ·(unknown), Ananda S Bandyopadhyay, Simona Zipursky, Laura Cooper, Chris Gast, (unknown), Ralf Clemens, Sue Ann Costa Clemens, (unknown), (unknown)	6
3	Pertussis antibodies and vaccination coverage among healthcare professionals in Brazil is inadequate: A cross-sectional serological study 2023 ·Vaccine ·(unknown), Lily Yin Weckx, Maria Isabel de Moraes‐Pinto, (unknown), (unknown), (unknown), (unknown), Ralf Clemens, Sue Ann Costa Clemens	2
4	Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study 2022 ·Open Forum Infectious Diseases ·Sue Ann Costa Clemens, Eveline Pı́polo Milan, Eduardo Sprinz, (unknown), (unknown), Ping Li, Huiling Chen, Igor Smolenov, Andrew J. Pollard, Ralf Clemens	9
5	Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial 2022 ·The Lancet Infectious Diseases ·Igor Smolenov, Htay Htay Han, Ping Li, Carmen Baccarini, Carole Verhoeven, Frank W. Rockhold, Sue Ann Costa Clemens, Donna M. Ambrosino, Peter Richmond, George R. Siber, Joshua G. Liang, Ralf Clemens	18
6	Lessons for strengthening childhood immunization in low- and middle-income countries from a successful public-private partnership in rural Nigeria 2021 ·International Health ·Aima A. Ahonkhai, Olumuyiwa O. Odusanya, François Meurice, Leslie Pierce, (unknown), (unknown), Ralf Clemens, Vincent I. Ahonkhai	4
7	Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials 2020 ·The Lancet ·Ilse De Coster, Isabel Leroux‐Roels, Ananda S Bandyopadhyay, Christopher Gast, Kanchanamala Withanage, Katie Steenackers, Philippe De Smedt, Annelies Aerssens, Geert Leroux‐Roels, M. Steven Oberste, Jennifer L. Konopka‐Anstadt, William C. Weldon, Alan Fix, John Konz, Rahnuma Wahid, John F. Modlin, Ralf Clemens, Sue Ann Costa Clemens, Novilia Sjafri Bachtiar, Pierre Van Damme	58
8	Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America 2017 ·Vaccine ·Eduardo López‐Medina, Mario Melgar, James Gaensbauer, Ananda S Bandyopadhyay, Bhavesh Borate, William C. Weldon, Ricardo Rüttimann, Joel I. Ward, Ralf Clemens, Edwin J. Asturias	9
9	Epidemiology and prevention of influenza in children in Argentina and Brazil 2017 ·Héctor Abate, Pablo Bonvehí, Ana Ceballos, Ralf Clemens, (unknown), (unknown), Ángela Gentile, Norberto Giglio, Silvia González Ayala, (unknown), Gabriel Wolf Oselka, Marco Aurélio Palazzi Sáfadi, (unknown), Ricardo Rüttimann, Daniel Stamboulián, Carla Vizzotti	2
10	Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial 2015 ·The Lancet Infectious Diseases ·Xavier Sáez‐Llorens, Ralf Clemens, Geert Leroux‐Roels, José Jimeno, Sue Ann Costa Clemens, William C. Weldon, M. Steven Oberste, (unknown), Ananda S Bandyopadhyay	34
11	Rotavirus Serotype G9 Is Associated with More‐Severe Disease in Latin America 2006 ·Clinical Infectious Diseases ·A. C. Linhares, Thomas Verstraeten, (unknown), Ralf Clemens, Thomas Breuer	53
12	Does the Concurrent Administration of an Inactivated Hepatitis A Vaccine Influence the Immune Response to Other Travelers Vaccines? 2006 ·Journal of Travel Medicine ·Hans L. Bock, J. P. Kruppenbacher, Ulrich Bienzle, (unknown), Friedrich Hofmann, Ralf Clemens	2
13	Soroprevalência para hepatite A e hepatite B em quatro centros no Brasil Hepatitis A and hepatitis B seroprevalence in four centers in Brazil 2000 ·Revista da Sociedade Brasileira de Medicina Tropical ·Sue Ann Costa Clemens, (unknown), (unknown), (unknown), Themis Reverbel da Silveira, (unknown), Ralf Clemens	3
14	Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children 1999 ·The Pediatric Infectious Disease Journal ·Vytautas Usonis, V. Bakasénas, Achim Kaufhold, (unknown), Ralf Clemens	57
15	Therapeutic effects of chloroquine in combination with quinine in uncomplicated falciparum malaria 1996 ·Annals of Tropical Medicine and Parasitology ·S Vanijanonta, (unknown), (unknown), (unknown), Ralf Clemens, S. Pukrittayakamee	14
16	Immunogenicity and reactogenicity of a combined hepatitis A/B candidate vaccine: first results 1996 ·Liver International ·B. Kallinowski, H.L. Bock, Ralf Clemens, Lorenz Theilmann	14
17	Accelerated Schedule for Hepatitis B Immunization 1995 ·Journal of Travel Medicine ·Hans L. Bock, Thomas Löscher, N. Scheiermann, R Baumgaŕten, Manfred Wiese, (unknown), Roland Sänger, Ralf Clemens	47
18	Hemodynamic profile of intravenous fenoldopam in patients with hypertensive crisis 1993 ·Journal of Molecular Medicine ·(unknown), (unknown), Ralf Clemens, H.-P. Schuster	22
19	Polymorphonuclear leucocyte elastase in Plasmodium falciparum malaria 1992 ·Transactions of the Royal Society of Tropical Medicine and Hygiene ·Sasithon Pukrittayakamee, Ralf Clemens, C Pramoolsinsap, Hermann Erich Karges, S Vanijanonta, D Bunnag, Nicholas J. White	22
20	Factor XIII: enzymatic and clinical aspects. 1988 ·PubMed ·(unknown), Ralf Clemens	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact